… pathogenic feature in many forms of cardiovascular disease, and the therapeutic potential of
sGC … across the broad spectrum of cardiovascular disease, explains the rationale behind the …

… disturbances-related diseases of the cardiovascular system has … of guanylate cyclases in
cardiovascular pharmacology. … spectrum of cardiovascular and non-cardiovascular disease. …

… Disrupted NO–sGC–cGMP signalling is a common pathogenic feature of many cardiovascular
diseases. Although clinical studies of sGC stimulators are currently focusing on the …

… It not only affects the respiratory system but also increases the risk of systemic manifestations
and serious comorbidities, such as cardiovascular disease, skeletal muscle dysfunction …

… has been shown to preferentially protect against diseases where sGC is down-regulated
because of oxidation, such as pulmonary hypertension or cardiovascular diseases (41, 42). …

… guanylate cyclases in the cardiovascular system [18]. Intracellular cGMP is synthesised by
guanylate cyclases… contributes to the development of cardiovascular diseases, some of which …

… guanylate cyclase (sGC)-cyclic guanosine 3′, 5′-monophosphate pathways in heart failure
and several new drugs that modify guanylate cyclase. … stress in cardiovascular disease. …

… guanylyl cyclases (sGCs) which catalyze cGMP production. Based on the important role of
NO-signaling in the cardiovascular … the cardiovascular disease space, like in fibrotic diseases …

… A central regulator of the circulatory system is the soluble guanylate cyclase (sGC). Two …
of pulmonary hypertension and could lead to new therapies for cardiopulmonary disease. …

… a unique mode of action with a broad treatment potential in cardiovascular diseases and
beyond. … directly bind to sGC and are allosteric modulators of guanylyl cyclase activity (Fig. 1). …